Ocrelizumab Clinical Trials
10 recruitingDrug
Phase 44Phase 33Phase 21
Showing 1–10 of 10 trials
Recruiting
Phase 3
Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.
Relapsing Multiple Sclerosis
Novartis Pharmaceuticals360 enrolled99 locationsNCT06846281
Recruiting
A Study to Investigate Effects of Ocrelizumab Treatment on Neurofilament Light Chain (NfL) Levels and Participant Satisfaction in Participants With Multiple Sclerosis (MS)
Multiple Sclerosis
Hoffmann-La Roche842 enrolled84 locationsNCT06780150
Recruiting
Phase 4
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Ocrelizumab in Participants With Relapsing Multiple Sclerosis and Primary Progressive Multiple Sclerosis
Relapsing Multiple SclerosisPrimary Progressive Multiple Sclerosis
Hoffmann-La Roche60 enrolled17 locationsNCT07483450
Recruiting
Phase 2
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489 as Add-on Therapy to Ocrelizumab, in Participants With Progressive Forms of Multiple Sclerosis (MS)
Progressive Multiple Sclerosis
Hoffmann-La Roche360 enrolled47 locationsNCT07282574
Recruiting
Phase 4
Ocrelizumab Discontinuation in Relapsing Multiple Sclerosis
Multiple Sclerosis
National Institute of Allergy and Infectious Diseases (NIAID)123 enrolled12 locationsNCT05285891
Recruiting
Phase 3
An Extension Study to Assess Impact of Multiple Sclerosis (MS) on Physical Function and Provide Continued Ocrelizumab Treatment
Multiple Sclerosis
Hoffmann-La Roche500 enrolled44 locationsNCT06675955
Recruiting
Phase 3
A Study of the Efficacy and Safety of BCD-281 in Patients With Relapsing-Remitting Multiple Sclerosis
Relapsing-remitting Multiple Sclerosis (RRMS)
Biocad292 enrolled1 locationNCT07321093
Recruiting
A Study to Learn More About The Safety of Diroximel Fumarate (VUMERITY®) in Participants Who Took it During Pregnancy And About the Health of Their Babies
Multiple Sclerosis
Biogen1,178 enrolled1 locationNCT05688436
Recruiting
Phase 4
Effects of Ocrelizumab Treatment on Immune Cells in Lymph Nodes in Multiple Sclerosis
Multiple Sclerosis, Relapsing-Remitting
University of California, San Francisco5 enrolled1 locationNCT06495593
Recruiting
Phase 4
B Cell Tailored Ocrelizumab Versus Standard Ocrelizumab in Relapsing Remitting Multiple Sclerosis
Multiple Sclerosis, Relapsing-Remitting
Amsterdam UMC, location VUmc296 enrolled1 locationNCT05296161